Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-02-21
1998-08-25
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514913, A67K 3135
Patent
active
057983801
ABSTRACT:
Methods for the treatment of glaucoma are described. The compounds described cause a perturbation of cell adhesions in the trabecular meshwork, mainly via disruption of the associated cytoskeletal structures or the modulation of their interactions with the underlying membrane. Perturbation of these adhesions reduces the resistance of the trabecular meshwork to fluid flow and thereby reduces intraocular pressure.
REFERENCES:
patent: 4170398 (1979-10-01), Koester
patent: 4757089 (1988-07-01), Epstein
patent: 5306731 (1994-04-01), Epstein
Embase Abstract of Journal Acta. Soc. Ophthamol JPN. 1992. Nagata et al.
Medline Abstract of Journal Experimental Eye Research 1987. Yoshimura et al.
Kaufman, P. L. and Mittag, T. W., "Medical Therapy of Glaucoma," Ch. 9, Sec. II (pp. 9.7-9.30) In P. L. Kaufman and T. W. Mittag (eds.): Glaucoma (vol. 7 of S.M. Podos and M. Yanoff (eds): Textbook of Ophthalmology Series). London, Mosby-Year Book Europe Ltd. (1994).
Guyton, A. C., Textbook of Medical Physiology (W. B. Saunders Co., Sixth Ed.), pp. 386-389 (1981).
The Merck Manual of Diagnosis and Therapy (16th Edition, 1992) Sec. 17: Ophthalmologic Disorders Subsec. 227: Glaucoma.
Schwartz, A. L., "Argon Laser Trabecular Surgery in Uncontrolled Phakic Open Angle Glaucoma," Opthalmology 88:203-212 (1981).
Wilensky J. T., and Jampol, L. M., "Lasr Therapy for Open Angle Glaucoma," Ophthalmology 88:213-217 (1981).
Current Surgical Diagnosis & Treatment (Eighth Edition, 1988), Appleton & Lange, Ch. 41, pp. 819-820.
AHFS Drug Information 93, Gerald K. McEvoy, ed., pp. 1729-1753 and 1767-1779 (1993).
Review of Medical Physiology, W. F. Ganong, Ch. 8: Vision (pp. 117-136), Appleton & Lange (Thirteenth Ed. 1987).
Alberts, B., et al., Molecular Biology of the Cell (Garland Publishing, Inc. 1994) Ch. 16 (pp. 787-861).
Darnell, J., et al., Molecular Cell Biology (Scientific American Books, Inc., 3rd. Edition, 1986) Ch. 19 (pp. 815-858).
Geiger, B., et al., "The Molecular Basis for the Assembly and Modulation of Adherens Type Junctions," Cell Diff. & Dev. 32:343-354 (1990).
Kaufman, P.L., and Barany, E. H., "Loss of Acute Pilocarpine Effect on Outflow Facility Following Surgical Disinsertion and Retrodisplacement of the Ciliary Muscle from the Sclera Spur in the Cynomolgus Monkey," Invest. Ophthalmol. 15:793-807 (1976).
Kaufman, P.L., and Barany, E. H., "Cytochalasin B Reversibly Increases Outflow Facility in the Eye of the Cynomolgus Monkey," Invest. Ophth. & Visual Science 16(1):47-53 (1977).
Spector, I., et al., "Latrunculins-Novel Marine Macrolides that Disrupt Microfilament Organization and Affect Cell Growth: I. Comparison with Cytochalasin D," Cell Motil. & Cytoskel. 13:127-44 (1989).
Croft, M. A., and Kaufman, P. L., "Effect of Daily Topical Ethacrynic Acid on Aqueous Humor Dynamics in Monkeys," Curr. Eye Res. 14:777-781 (1995).
Bill, A., et al., "Effects of Intracameral Na.sub.2 EDTA and EGTA on Aqueous Outflow Routes in the Monkey Eye," Invest. Ophthalmol. Vis. Sci. 19:492-504 (1980).
Bill, A., "Basic Physiology of the Drainage of Aqueous Humor," In: Bito, L. Z., et al. eds., The Ocular and Cerebrospinal Fluids. Fogarty International Center Symposium (London) Academic Press, Exp. Eye Res. (Supp.):291-304 (1977).
U.S. DHHS. Vision Research--A National Plan: 1983-87. 1987 Evaluation and Update. Report of the National Advisory Eye Council 1987 NIH Publication No. 87-2755:231-278.
Barany, E. H., "Simultaneous Measurements of Changing Intraocular Pressure and Outflow Facility in the Vervet Monkey by Constant Pressure Infusion," Invest. Ophthalmol. 3(2):135-143 (1964).
Menage, M. J., et al., ".epsilon.-Aminocaproic Acid Does Not Inhibit Outflow Resistance Washout in Monkeys," Invest. Ophthalmol Vis. Sci. 36(9):1745-1749 (1995).
Hadari, Y. R., et al., "Hepatic Tyrosine-phosphorylated Proteins Identified and Localized Following in Vivo Inhibition of Protein Tyrosine Phosphatases: Effects of H.sub.2 O.sub.2 and Vanadate Administration into Rat Livers," Mol. Cell. Endocrinol. 97:9-17 (1993).
Volberg, T., et al., "The Effect of Tyrosine-Specific Protein Phosphorylation on the Assembly of Adherens-type Junctions,"EMBO J 11:1733-1742 (1992).
Gupta, N., et al., "Muscarinic Receptor M1 and M2 Subtype in the Human Eye: QNB, Pirenzipine, Oxotremorine, and AFDX-116 in Vitro Autoradiography," Br. J. Ophthalmol. 78:555-559 (1994).
Zhang, X., et al., "Expression of Muscarinic Receptor Subtype mRNA in the Human Ciliary Muscle," Invest. Ophthalmol. Vis. Sci. 36:1645-1657 (1995).
Volberg, T., et al., "Effect of Protein Kinase Inhibitor H-7 on the Contractility, Integrity, and Membrane Anchorage of the Microfilament System," Cell Motil. Cytoskel. 29:321-338 (1994).
Tamaoki, T., et al., "Staurosporine, A Potent Inhibitor of Phospholipid/Ca.sup.++ -Dependent Protein Kinase," Biochem. Biophys. Res. Commun. 135(2):397-402 (1986).
Matsumoto H., and Sasaki, Y., "Staurosporine, A Protein Kinase C Inhibitor Interferes with Proliferation of Arterial Smooth Muscle Cells,"Biochem. Biophys. Res. Commun. 158(1):105-09 (1989).
Nakansihi, S., et al., "KT5926, a Potent and Selective Inhibitor of Myosin Light Chain Kinase," Mol. Pharmacol. 37:482-488 (1990).
Isemura, M., et al., "Myosin Light Chain Kinase Inhibitors ML-7 and ML-9 Inhibit Mouse Lung Carcinoma Cell Attachment to the Fibronectin Substratum," Cell Bio. Int. Rep. 15(10):965-972 (1991).
Kashman, Y., et al., "Latrunculin, a New 2-thiazolidinione Macrolide from the Marine Sponge Latrunculia Magnifica," Tetrahedron Lett. 21:3629-3632 (1980).
Bubb, M. R., et al., "Swineholide A is a Microfilament Disrupting Marine Toxin That Stabilizes Actin Dimers and Severs Actin Filaments," J. Biol. Chem. 270:3463-3466 (1995).
Volberg, T., et al., "Modulation of Intercellular Adherens-type Junctions and Tyrosine Phosphorylation of Their Components in RSV-transformed Cultured Chick Lens Cells," Cell Regulation 2:105-120 (1991).
Kaufman, P. L., and Lutjen-Drecoll, E., "Total Iridectomy In The Primate in vivo: Surgical Technique and Postoperative Anatomy," Invest. Ophth. 14:766-771 (1975).
Gabelt, B. T., and Kaufman, P. L. "Prostaglandin F.sub.2.alpha. Increases Uveoscleral in the Cynomolgus Monkey," Exp. Eye Res. 49:389-402 (1989).
Kam, A., et al., "Mapping of Adherens Junction Components Using Microscopic Resonance Energy Transfer Imaging," J. Cell Sci. 108:1051-1062 (1995).
Poyer, J. F., et al., "Age Does Not Affect Contractile Responses of the Isolated Rhesus Monkey Ciliary Muscle to Muscarinic Agonists," Curr. Eye Res. 12(5):413-422 (1993).
Poyer, J. F., et al., "Prostaglandin F.sub.2.alpha. Effects on Isolated Rhesus Monkey Ciliary Muscle," Invest. Ophth. Vis. Sci. 36:2461-2465 (1995).
Kaufman, P. L., and Wallow, I. H., "Minified Diagnostic Contact Lenses for BIomicroscopic Examination and Photocoagulation of the Anterior and Posterior Segment in Small Primates," Exp. Eye Res. 40:883-885 (1985).
Carmely, S., and Kashman, Y., "Structure of Swinholide-A, a New Macrolide from the Marine Sponge Theonella Swinhoei," Tetrahedron Lett. 26:511-514 (1985).
Kase, H., et al., "K-252a, a Potent Inhibitor of Protein Kinase C from Microbial Origin," J. Antibiotic. (Tokyo) 39:1059-1065 (1986).
Robinson, J. C., and Kaufman, P. L., "Cytochalasin B Potentiates Epinephrine's Outflow Facility-Increasing Effect," Invest. Ophthalmol Vis Sci 32(4):1614-16 (1991).
Quick, J., et al., "The Structure and Biological Activities of the Widely Used Protein Kinase Inhibitor, H7, Differ Depending on the Commercial Source," Biochem. Biophys. Res. Comm. 187(2):657-63 (1992).
Paterson, I., et al., "Total Synthesis of (-)-Preswinholide A," J. Am. Chem. Soc. 116:2615-16 (1994).
Geiger Benjamin
Kaufman Paul L.
Fay Zohreh
Wisconsin Alumni Research Foundation
LandOfFree
Cytoskeletal active agents for glaucoma therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytoskeletal active agents for glaucoma therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytoskeletal active agents for glaucoma therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-36683